Stockscreener 앱 받기
33.95
4.60%
1.565
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat
Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus
Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Stoke Therapeutics, Inc. $STOK Shares Purchased by Franklin Resources Inc. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $267,723.36 in Stock - MarketBeat
Jonathan Allan Sells 8,785 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,018 Shares of Stock - MarketBeat
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 3,662 Shares - MarketBeat
Allan Jonathan of Stoke Therapeutics sells $306k in shares By Investing.com - Investing.com South Africa
Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com India
Allan Jonathan of Stoke Therapeutics sells $306k in shares - Investing.com
Stoke Therapeutics Executives Conduct Multiple Stock Sales - TradingView — Track All Markets
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Fly 36% But Investors Aren't Buying For Growth - 富途牛牛
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Zorevunersen shows promise for Dravet syndrome in long-term data By Investing.com - Investing.com South Africa
Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting - TipRanks
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke Therapeutics, Inc. and Biogen Present Data on Zorevunersen at AES 2025 - TradingView — Track All Markets
Biogen and Stoke Therapeutics Present Promising Long-term Data for Zorevunersen in Treating Dravet Syndrome at AES 2025 - Quiver Quantitative
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - The Manila Times
Biogen (Nasdaq: BIIB) and Stoke share long-term Dravet data on zorevunersen - Stock Titan
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry - simplywall.st
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 1,066 Shares - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $61,729.10 in Stock - MarketBeat
Stoke Therapeutics: A Long-Term Biotech Growth PlayWhy I Assign A Hold Rating (STOK) - Seeking Alpha
Geode Capital Management LLC Has $11.04 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 2,292 Shares of Stock - MarketBeat
Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 By Investing.com - Investing.com South Africa
Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 - Investing.com Nigeria
Can Stoke Therapeutics Inc. stock beat analyst upgradesJuly 2025 Sector Moves & Risk Managed Trade Strategies - Newser
Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples? - simplywall.st
A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge - Yahoo Finance
Price-Driven Insight from (STOK) for Rule-Based Strategy - news.stocktradersdaily.com
Biogen and Stoke Therapeutics Present Promising Zorevunersen Data for Dravet Syndrome at 2025 American Epilepsy Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Biogen
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire
Advantage Alpha Capital Partners LP Purchases Shares of 17,888 Stoke Therapeutics, Inc. $STOK - MarketBeat
Can Stoke Therapeutics (STOK) Translate Natural History Data Into a Competitive Edge for Dravet Therapy? - simplywall.st
Kennondale Capital Management LLC Grows Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Insider Sell: Adrian Krainer Sells 40,472 Shares of Stoke Therap - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Stoke Therapeutics (STOK): Evaluating Valuation Following Key Dravet Syndrome Study Results Published in Neurology - simplywall.st
0.56%
1.23%
자본화:
|
볼륨(24시간):